Journal
THERAPEUTIC ADVANCES IN HEMATOLOGY
Volume 12, Issue -, Pages -Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/2040620720986641
Keywords
erythropoiesis-stimulating agents; hypomethylating agents; lenalidomide; low-risk myelodysplastic syndromes; luspatercept
Categories
Ask authors/readers for more resources
Myelodysplastic syndromes (MDS) are characterized by bone-marrow failure, with anemia as the most common cytopenia in low-risk MDS patients. Current treatment options for MDS have limited durable responses and significant adverse effects, with chronic transfusions carrying risks. Luspatercept, a recently approved therapy for LR-MDS with ring sideroblasts, has shown improvement in transfusion independence with a well-tolerated safety profile.
Myelodysplastic syndromes (MDS) are a spectrum of clonal stem-cell disorders characterized clinically by bone-marrow failure. Resultant cytopenias are responsible for significant mortality and decreased quality of life in patients with MDS. In patients with low-risk MDS (LR-MDS), anemia is the most common cytopenia and erythropoiesis-stimulating agents (ESA) are usually used as first-line therapy. Those patients who become refractory to ESA have a poor survival. Available treatment options such as lenalidomide, hypomethylating agents, and immunosuppressive therapy can provide some hematologic response among selected subsets of patients, however durable responses are limited, and these agents can carry significant adverse effects. Chronic transfusions help to alleviate symptoms of anemia but still carry risks associated with transfusion and iron overload. Luspatercept, recently approved for those LR-MDS with ring sideroblasts refractory to ESA, was found to have an improvement in transfusion independence with a well-tolerated safety profile. While anemia is the most common cytopenia, thrombocytopenia and neutropenia management is challenging and the co-occurrence of these cytopenias with anemia may dictate the choice of therapy. In this article, we review LR-MDS and discuss the optimal use of current treatment options and explore new therapeutic options on the horizon.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available